So why would I need a Biomarker Audit if I feel fine? Feeling fine and being fine are different claims and only one of them can be measured. Atherosclerosis produces no symptoms until a plaque ruptures or narrows an artery past the point of compensation. Insulin resistance produces none until the compensation fails. A rising ApoB has never once announced itself with a feeling. The biomarkers that predict heart attack, stroke and type 2 diabetes move for years before anything hurts. That is why the people who discover them late describe the discovery the same way. Everything felt fine right up until it did not. The Biomarker Audit exists to move that discovery to a quarter when the numbers can still be moved back. Here is what silent progression actually looks like, which markers catch it and what a measured baseline is worth.
- Atherosclerosis and insulin resistance are silent for years and the first symptom is often the event itself.
- ApoB, Lp(a), fasting insulin and hs-CRP move years before symptoms and are rarely on routine panels.
- One in five people carry elevated Lp(a), an inherited risk marker most never know they have.
- The Biomarker Audit reads nine biomarkers as one system every 90 days inside the flat $299 membership.
- A baseline drawn today is the reference every future decision is made against.
What silent progression actually looks like
The cardiovascular disease process starts decades before the event. Lipoprotein particles enter the artery wall in early adulthood, the plaques grow slowly and the narrowing that produces chest pain or shortness of breath typically represents advanced disease. The trial evidence that reshaped prevention in the last decade made the mechanism explicit, that atherosclerotic disease is driven by the circulating burden of apolipoprotein B carrying lipoproteins across a lifetime and that lowering that burden earlier compounds the benefit. The person who feels fine at fifty with an untreated elevated ApoB is not healthy by the number that matters. They are early in a process that has not yet produced a sensation.
Insulin resistance runs the same movie on a different clock. The pancreas compensates for resistant tissues by secreting more insulin, glucose stays normal for years and the fasting glucose on the routine panel reads fine the whole time. Fasting insulin is the measurement of that compensation and by the time the glucose or the HbA1c rises, the compensation has been failing for a while. The fatigue, the central weight gain and the cravings that eventually appear are late signals. The early signal is a number nobody drew.
The first symptom of atherosclerosis is often the last warning. The markers that predict it are measurable a decade earlier and they cost a few tubes of blood.
The four markers that see around the corner
Apolipoprotein B counts the atherogenic particles directly, one molecule per particle and it is the closest thing the lipid family has to a measure of what actually enters the artery wall. It can be elevated while the standard cholesterol lines read normal, which is precisely the case a routine panel misses. Lipoprotein (a) is inherited, fixed for life and measured once and an estimated one in five people carry an elevated level that changes how aggressively every other risk factor should be managed. Fasting insulin reads the insulin compensation years before glucose moves. hs-CRP reads the inflammatory component that turns a lipid problem into an event. Four tubes, one draw and the picture the annual physical never assembled is on the page.
The Biomarker Audit reads these alongside a full lipid panel, HbA1c, a comprehensive metabolic panel, a CBC with differential and platelets and TSH with reflex to free T4, with hormone levels added when clinically indicated, through the Beluga Health lab network. It repeats every 90 days because the value of a marker is the trend and a trend requires more than one point. The audit is included in the membership at one flat $299 a month, four panels a year, with no per-test charge.
What a baseline is actually worth
The strongest argument for drawing the panel while you feel fine is not the detection itself, it is the reference point it creates. A person whose ApoB is measured at forty has a number to compare every future draw against and the decisions that follow are anchored in their own trajectory rather than in population tables. The person whose first ApoB is drawn at sixty-two during a cardiac workup has no trend, no baseline and no answer to the question of how long the burden has been building. Medicine can act on a snapshot. It manages far better with a movie and the movie has to start somewhere.
There is a behavioral truth in this as well and it is worth stating without judgment. People act on measured numbers in a way they never act on generalized advice. The annual lecture about diet and exercise changes almost nobody's behavior because it carries no number attached to their own body. A fasting insulin that reads high against your own baseline two quarters in a row changes decisions, because the drift is personal and the recheck is scheduled. The quarterly cadence is not an indulgence for the worried well. It is the feedback loop that makes preventive effort real.


Who this is genuinely for and who it is not
We will be honest about the boundaries, because screening without purpose is its own failure mode. If you already have a clinician who orders the full marker set annually, reviews it with you and acts on it, you have what the audit provides and you should keep that relationship. If you are at the end of life or managing advanced illness where biomarker optimization is not the priority, this is not the product for that season. And if the idea of knowing your numbers fills you with dread rather than curiosity, forcing the panel on yourself is not our sales pitch, because the value of a measured life depends on what you intend to do with it.
The reader this is built for is the one who intends to be well for decades, who would rather catch a rising ApoB at forty-two than a blocked artery at fifty-eight and who wants one clinician reading the whole system every quarter instead of an annual checkbox. For that reader, feeling fine is not an argument against the panel. It is the moment the panel is worth the most, because the numbers are cheapest to move while nothing hurts.
What it costs to start
The membership is one flat $299 a month covering the clinical relationship, four quarterly Biomarker Audits, asynchronous messaging with the care team and video visits and your own health platform, where every result, visit and medication builds into one Health Story with Cassandra to help you understand your numbers. It starts with a $598 hold on your card covering the first two months, charged only once a clinician accepts you into care and released if the clinician cannot accept you. Once accepted, the first two months are charged and nonrefundable and from month three the membership is month to month. Any prescription, where a clinician judges one indicated, is billed by the pharmacy you choose at that pharmacy's own price and we take nothing on it. One flat fee for the doctor and zero markup on the medicine.
Care is delivered by licensed physicians of Beluga Health, P.A., an independent Florida professional corporation licensed to practice in all 50 states, working under GoodLife Health's clinical protocols. The eligibility check takes a few minutes and a clinician reviews every application and you are never charged unless you are accepted into care.
FAQ
I feel fine. Why would I need a Biomarker Audit?
Because the conditions the panel predicts, atherosclerosis and insulin resistance above all, produce no symptoms for years and the markers that track them, ApoB, Lp(a), fasting insulin and hs-CRP, move long before anything hurts. Feeling fine is not a lab result.
What does the audit include?
ApoB, Lp(a), hs-CRP, HbA1c, fasting insulin, a full lipid panel, a comprehensive metabolic panel, a CBC with differential and platelets and TSH with reflex to free T4, with hormone levels added when clinically indicated. It repeats every 90 days through the Beluga Health lab network.
Is Lp(a) really measured only once?
Yes. It is genetically determined and stable across life, so one measurement is enough. That one measurement matters because an elevated result, found in roughly one in five people, changes how aggressively every other risk factor should be managed.
Can my cholesterol be normal and my risk still be high?
Yes. The composite cholesterol numbers count mass while the artery responds to particle number and ApoB counts the particles. A normal standard panel with an elevated ApoB is one of the most common findings in a complete workup.
How often is the panel repeated?
Every 90 days, four times a year, inside the membership fee. The value of a biomarker is its trend and a quarterly cadence catches the drift an annual snapshot misses.
What if everything comes back normal?
Then you have a baseline, which is the reference every future decision is made against and you have ruled out the silent drivers rather than assumed them away. A clean panel is a result, not a wasted draw.
What does it cost?
The membership is one flat $299 a month with a $598 hold covering the first two months, charged only once a clinician accepts you and released if the clinician cannot accept you. Four audits a year sit inside the fee and medication is billed separately by your pharmacy at its own price.
One last thing
Every cardiac event has a decade of warning signs behind it and almost none of them produced a feeling. The panels that read those warnings exist, they cost less than most people spend on a month of unexamined habits and the only question is whether the draw happens this year or during the workup. Feeling fine is the best time to find out what fine is made of.
Related guides
- ApoB and LDL: which number predicts heart attack risk
- Lipoprotein(a), the inherited risk marker
- The definitive guide to cardiometabolic optimization
- Cardiometabolic optimization at GoodLife Health
References
- Ference BA et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease, European Heart Journal, 2017. pubmed.ncbi.nlm.nih.gov/28244393
- Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement, 2022. pubmed.ncbi.nlm.nih.gov/36036785
- Arnett DK et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, Circulation, 2019. doi.org/10.1161/CIR.0000000000000678